

CYC116


SYN-1034

4-(2-amino-4-methylthiazol-5-yl)-N-(4-morpholinophenyl)pyrimidin-2-amine

CAS Registry No.: 693228-63-6

Smiles String:

CC1=C(SC(=N1)N)C2=NC(=NC=C2)NC3=CC=C(C=C3)N4CCOCC4



Molecular Weight: 368.46

Molecular Formula: C₁₈H₂₀N₆O_S

Lot Number: Refer to vial

¹H-NMR: Available on request


HPLC (Purity): > 95.0% @ 254 nm

ES-MS: Available on request


Description:

CYC116 is an orally active small molecule multi-kinase inhibitor with anti-neoplastic activity. CYC116 inhibits Aurora kinases A/B and vascular endothelial growth factor receptor 2 (VEGFR2), resulting in disruption of the cell cycle, rapid cell death, and the inhibition of angiogenesis.

Biological Activity



Kinome Mapping



Shipping and Storage Temperature

Shipping:
Ambient

Storage:
2 years -20C, Powder 1 month, -4C in DMSO, More than one month -80C in DMSO

Solubility

DMSO 24mg/mL, Ethanol 1mg/mL

Preparing Stock Solutions

Stock Solution (1ml DMSO)	1mM	10mM	20mM	50mM
Mass(mg)	0.3685	3.6850	7.3700	18.4250

References

1. Pollard JR, Mortimore M . Discovery and development of aurora kinase inhibitors as anticancer agents. J Med Chem. 2009 May 14;52(9):2629-51. doi: 10.1021/jm8012129.
2. Gao C, Cahya S, Nicolaou CA, Wang J, Watson IA, Cummins DJ, Iversen PW, Vieth M . Selectivity data: assessment, predictions, concordance, and implications. J Med Chem. 2013 Sep 12;56(17):6991-7002. doi: 10.1021/jm400798j. Epub 2013 Aug 30.
3. Pollard JR, Mortimore M . Discovery and development of aurora kinase inhibitors as anticancer agents. J Med Chem. 2009 May 14;52(9):2629-51. doi: 10.1021/jm8012129.

Ordering Information

To order more of this or any other SYNkinase compound, go to synkinase.com, Call us Toll Free (US Only) at 1- 877-854-6273 or email orders@synkinase.com.

Product Datasheet (Rev. 1.1)